Search for: [Abstract = "Ovarian cancer in the early stages of development does not cause symptoms, so at the time of diagnosis, most patients are in III or stage IV according to FIGO, with a low 5\-years' survival. Endometriosis is a very common disease, characterized by the lack of effective treatments and an increased risk of developing ovarian cancer. The study of cancer immunology, hypotheses reduced the effectiveness of the immune system in endometrial ectopia endometriosis and predisposed to ovarian cancer, suggest that underlying these diseases may be a phenomenon of escape from immune surveillance of cancer. Ovarian cancer and endometriosis have demonstrated the ability to regulate the activity of the immune system. HLA\-G is a non\-classical histocompatibility antigen, which inhibits the immune system. It is also found in soluble form in serum. It has been shown to increase expression of HLA\-G together with the progression of cancer, but there is a lack of clinical applications of HLA\-G, and no data about the serum concentration of HLA\-G in patients operated on. Increased expression of HLA\-G has been demonstrated in ectopic endometrium in the peritoneal fluid of women with endometriosis. There is no evidence of the sHLA\-G in endometriosis located in the peritoneal cavity. Aim of this study was to assess the levels of sHLA\-G in the serum of women surgically treated for deep endometriosis"]

Number of results: 1